Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Scorletti , E., Calder, P. C. and Byrne, C. D. (2011) Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine, 40, (3), 332-343. (doi:10.1007/s12020-011-9530-x). (PMID:21894514).
Full text not available from this repository.
Non-alcoholic fatty liver disease (NAFLD) is
usually a silent disease that occurs in a very high proportion
of people with features of the metabolic syndrome,
including overweight, insulin resistance and type 2 diabetes.
Because obesity and type 2 diabetes are now extremely
common in Westernised societies, it is likely that the
prevalence of NAFLD increases markedly in the future.
Although previously it was thought that NAFLD was
harmless, it is now recognised that NAFLD can be a progressive
liver condition that increases risk of cirrhosis, endstage
liver disease and hepatocellular carcinoma. Additionally,
liver fat accumulation causes insulin resistance
and increases risk of type 2 diabetes. Increasing evidence
now shows NAFLD is a risk factor for cardiovascular
disease (CVD). The purpose of this review is to briefly
discuss the pathogenesis of NAFLD, to describe the relationship
between NAFLD and CVD and the mechanisms
linking both conditions and to discuss some of the treatment
options (including lifestyle, nutrition and drugs) that
may influence both NAFLD and risk of CVD.
|Keywords:||Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH, cardiovascular disease (CVD, metabolic syndrome, inflammation, non-esterified fatty acids|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculty of Medicine > Human Development and Health
|Date Deposited:||29 Nov 2011 10:25|
|Last Modified:||29 Nov 2011 10:25|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)